In a group of 69 patients receiving levamisole the drug had to be discontinued in 15 (21-7%) because of intolerable but reversible side-effects including gastrointestinal upset, "flu-like" syndrome, central nervous system disturbances, and skin rash. Reversible agranulocytosis with life-threatening sepsis occurred in a patient receiving levamisole immunotherapy for colonic carcinoma. Neutrophils and platelets were both severely affected. Levamisole-dependent leucoagglutinins appeared with circulating immune complexes during the acute phase of the illness, suggesting an immune drug reaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(77)92386-8 | DOI Listing |
Publication Analysis
Top Keywords
receiving levamisole
8
complications cancer
4
cancer immunotherapy
4
immunotherapy levamisole
4
levamisole group
4
group patients
4
patients receiving
4
levamisole drug
4
drug discontinued
4
discontinued 21-7%
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!